BioVie Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioVie Inc. on October 1, 2018, reporting events effective as of that date. The company is incorporated in Nevada and operates as a biopharmaceutical entity.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and administrative changes rather than financial performance.
Material Changes
- Board of Directors: Julie Anderson resigned from the Board of Directors. The company will not replace her, reducing the board size to seven members.
- Executive Management: J. Wendy Kim, CPA, was appointed Chief Financial Officer, replacing R. Richard Wieland II, who served as interim CFO for the past year.
- Corporate Address: The company's principal executive offices and location of books and records moved from Beverly, Massachusetts, to Los Angeles, California.
Outlook, Risks, and Management Commentary
Management expressed appreciation for the service of the departing director and interim CFO. Ms. Kim brings over 25 years of accounting experience to the CFO role. The filing does not contain specific guidance, risk factors, or contingencies beyond the operational changes noted.
Key Facts for Investor Verification
- Confirm the new CFO's background and tenure at BioVie Inc.
- Verify the operational impact of the relocation from Massachusetts to California.
- Review the composition of the remaining seven-member Board of Directors.
- Check subsequent filings for the company's next financial report to assess liquidity and cash burn rates.